Longitudinal ctDNA monitoring in patients with metastatic uveal melanoma undergoing isolated hepatic perfusion in combination with ipilimumab and nivolumab.

Immunooncol Technol · 2025 · PMC12682135 · PMID 41362699

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a numerical trendno p-value reported

Although based on a very small number of patients with evaluable ctDNA response ( n = 6), ctDNA clearance at 3 months showed a numerical trend toward improved OS and PFS ( Supplementary Figure S1 B and C, available at https://doi.org/10.1016/j.iotech.2025.101079 ).

also in 669 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.